Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422745 · ClinicalTrials.gov registry record · Phase 4
COcoa Supplement and Multivitamin Outcomes Study
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 21,442
- Enrollment target
NCT02422745: Completed Phase 4 study, sponsored by Brigham and Women's Hospital.
NCT02422745 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 21,442 participants, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (4055% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02422745, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21,442 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether taking daily, dietary supplements of cocoa extract (containing cocoa flavanols and theobromine from the cocoa bean) and/or a standard multivitamin reduces the risk of developing cardiovascular disease (including heart attack, stroke, coronary revascularization, unstable angina or acute coronary syndrome (ACS) requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty, and cardiovascular mortality) and cancer.
Primary Outcome
CVD events include myocardial infarction, stroke, cardiovascular deaths, coronary revascularization procedures, unstable angina or acute coronary syndrome (ACS) requiring hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty. CVD events are confirmed by review of discharge summaries, ECG's, laboratory reports, test reports, radiology reports, surgical reports, medical records for reports of increased pain, use of medication to alleviate pain, and evidence of tropo
Interventions
- DIETARY_SUPPLEMENT Multivitamin
- DIETARY_SUPPLEMENT Cocoa extract
- DIETARY_SUPPLEMENT Cocoa extract placebo
- DIETARY_SUPPLEMENT Multivitamin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,442 participants |
| Start Date | 2015-06 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 4 |
What the finished NCT02422745 record still lists
NCT02422745 is an interventional study that assigns participants to a tested intervention. Its 21,442 participants enrollment target places it among the larger protocols in the corpus, above the 516-participant average among 9,235 other Phase 4 trials with a reported enrollment target (4055% higher).
The record links to 0 conditions, and to 4 interventions - of which Multivitamin is the first listed.
NCT02422745 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02422745 about?
NCT02422745 is a clinical study titled "COcoa Supplement and Multivitamin Outcomes Study". The purpose of this study is to determine whether taking daily, dietary supplements of cocoa extract (containing cocoa flavanols and theobromine from the cocoa bean) and/or a standard multivitamin reduces the risk of developing cardiovascular disease (including heart attack, stroke, coronary revascu...
What is the current status of trial NCT02422745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21,442 participants. The study started on 2015-06. Estimated completion is 2023-06-05.
What interventions are being tested in trial NCT02422745?
The interventions under investigation include: Multivitamin (DIETARY_SUPPLEMENT), Cocoa extract (DIETARY_SUPPLEMENT), Cocoa extract placebo (DIETARY_SUPPLEMENT), Multivitamin placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02422745?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02422745's enrollment target sits among peer trials
21,442 5th of 2000 higher than 1,996 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06047041 · 21,350 participants · NA
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
- NCT07213531 · 21,000 participants
Enhanced Valves Interventions and Safe AI Generated End Results
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia